Search

Eliot H Ohlstein

from Glenmoore, PA
Age ~70
Get Report
Also known as:
Eliot Dr Ohlstein, Eliot Howard Ohlstein, Elliott H Ohlstein, Eliot H Adair, Eliot H Olstein, Elliot Ohlstein
Phone and address:
15 Yeaton Ln, Glenmoore, PA 19343
(610) 458-8369
Related to:
Aurelio Puente, 29Kerri A Ohlstein, 39Casey Ohlstein, 41Ann OhlsteinJudy Lee, 52
Connected to:
Tina L Ohlstrom, 66Heather Ohlund, 46Richard A Ohlweiler, 93Claire L Ohlwiler, 110Reid Ohlwine, 29Duane Ohly, 67Alaina C Ohm, 28Dana M Ohm, 51Divyam K Ohm, 45Edith B Ohm, 93

Eliot Ohlstein Phones & Addresses

  • 15 Yeaton Ln, Glenmoore, PA 19343 (610) 458-8369
  • 1695 Scenic Gulf Dr, Miramar Beach, FL 32550 (850) 837-5992
  • Destin, FL
  • King of Prussia, PA
  • Plymouth Meeting, PA
  • Delray Beach, FL
  • 15 Yeaton Ln, Glenmoore, PA 19343

Work

Company: Altherx pharmaceuticals, inc. Jul 2009 Position: Chief scientific officer, head r&d

Education

Degree: Ph.D. School / High School: Tulane University School of Medicine 1977 to 1982 Specialities: Pharmacology

Skills

Drug Discovery • Pharmacology • Pharmaceutical Industry • Biotechnology • Clinical Trials • Clinical Development • Drug Development • R&D • Life Sciences • Lifesciences • Immunology • Oncology • Biopharmaceuticals • Cro • Biochemistry • Molecular Biology • Due Diligence • In Vitro • Technology Transfer • Neuroscience • Cancer • Regulatory Affairs • Assay Development • Cell Biology • Translational Medicine • Cell • Drug Delivery • Biomarkers • Expert Witness • Pharmaceuticals • Cro Management • Research and Development

Industries

Pharmaceuticals

Professional Records

License Records

Eliot Howard Ohlstein

Address:
Glenmoore, PA 19343
License #:
RP033893R - Active
Category:
Pharmacy
Type:
Pharmacist

Resumes

Resumes

Eliot Ohlstein Photo 1

Chief Scientific Officer

View page
Location:
15 Yeaton Ln, Glenmoore, PA 19343
Industry:
Pharmaceuticals
Work:
AltheRx Pharmaceuticals, Inc. since Jul 2009
Chief Scientific Officer, Head R&D
Drexel University College of Medicine since Jun 2009
Adjunct Professor Pharmacology
Benchmark Consulting Group Apr 2009 - 2011
Partner
Venuvics Pharmaceuticals 2008 - Mar 2009
CEO and Founder
GlaxoSmithKline 1982 - 2008
Senior Vice President Drug Discovery
Education:
Tulane University School of Medicine 1977 - 1982
Ph.D., Pharmacology
Skills:
Drug Discovery
Pharmacology
Pharmaceutical Industry
Biotechnology
Clinical Trials
Clinical Development
Drug Development
R&D
Life Sciences
Lifesciences
Immunology
Oncology
Biopharmaceuticals
Cro
Biochemistry
Molecular Biology
Due Diligence
In Vitro
Technology Transfer
Neuroscience
Cancer
Regulatory Affairs
Assay Development
Cell Biology
Translational Medicine
Cell
Drug Delivery
Biomarkers
Expert Witness
Pharmaceuticals
Cro Management
Research and Development

Publications

Us Patents

Pharmaceutical Combinations Of Beta-3 Adrenergic Receptor Agonists And Muscarinic Receptor Antagonists

View page
US Patent:
8642661, Feb 4, 2014
Filed:
Aug 2, 2011
Appl. No.:
13/196068
Inventors:
Stephen Caltabiano - King of Prussia PA, US
Eliot Ohlstein - Glenmoore PA, US
Stewart McCallum - King of Prussia PA, US
Assignee:
Altherx, Inc. - Glenmoore PA
International Classification:
A01N 33/02
A61K 31/135
A01N 33/00
A61K 31/13
A61K 31/16
A01N 43/04
A61K 31/70
US Classification:
514646, 514579, 514 25, 514659
Abstract:
Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.

Method Of Treating Isolated Systolic Hypertension

View page
US Patent:
20010005723, Jun 28, 2001
Filed:
Feb 6, 2001
Appl. No.:
09/777371
Inventors:
David Brooks - West Chester PA, US
Giora Feuerstein - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Robert Ruffolo - Spring City PA, US
Assignee:
SmithKline Beecham Corporation
International Classification:
A61K031/47
US Classification:
514/310000
Abstract:
This invention relates to the use of eprosartan to treat isolated systolic hypertension.

Method Of Treating Isolated Systolic Hypertension

View page
US Patent:
20020040045, Apr 4, 2002
Filed:
Oct 24, 2001
Appl. No.:
09/999808
Inventors:
David Brooks - West Chester PA, US
Giora Feuerstein - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Robert Ruffolo - Spring City PA, US
Assignee:
SmithKline Beecham Corporation
International Classification:
A61K031/4178
US Classification:
514/397000
Abstract:
This invention relates to the use of eprosartan to treat isolated systolic hypertension.

Use Of Factor Xiiia Inhibitors To Treat Atherosclerosis

View page
US Patent:
20020107177, Aug 8, 2002
Filed:
Apr 3, 2002
Appl. No.:
10/114787
Inventors:
Anne Arnold - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Assignee:
SmithKline Beecham Corporation
International Classification:
C12Q001/37
A61K038/00
US Classification:
514/002000, 435/023000
Abstract:
A method of treating a mammal, preferably a human, having atherosclerotic disease is provided. The method comprises administering to the mammal an inhibitor of Factor XIIIa which is involved in the formation of atherosclerotic lesions. Methods for identifying Factor XIIIa inhibitors are also provided.

Method Of Treating Isolated Systolic Hypertension

View page
US Patent:
20030045561, Mar 6, 2003
Filed:
Sep 19, 2002
Appl. No.:
10/247035
Inventors:
David Brooks - West Chester PA, US
Giora Feuerstein - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Robert Ruffolo - Spring City PA, US
Assignee:
SmithKline Beecham Corporation
International Classification:
A61K031/4178
US Classification:
514/397000
Abstract:
This invention relates to the use of eprosartan to treat isolated systolic hypertension.

Use Of Factor Xiiia Inhibitors To Treat Atherosclerosis

View page
US Patent:
20040105861, Jun 3, 2004
Filed:
Nov 25, 2003
Appl. No.:
10/722081
Inventors:
Anne Arnold - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Assignee:
SmithKline Beecham Corporation
International Classification:
A61K039/395
G01N033/53
US Classification:
424/145100, 435/007100
Abstract:
A method of treating a mammal, preferably a human, having atherosclerotic disease is provided. The method comprises administering to the mammal an inhibitor of Factor XIIIa which is involved in the formation of atherosclerotic lesions. Methods for identifying Factor XIIIa inhibitors are also provided.

Method Of Treating Isolated Systolic Hypertension

View page
US Patent:
20050113431, May 26, 2005
Filed:
Dec 14, 2004
Appl. No.:
11/012041
Inventors:
David Brooks - West Chester PA, US
Giora Feuerstein - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Robert Ruffolo - Spring City PA, US
International Classification:
A61K031/4184
US Classification:
514381000
Abstract:
This invention relates to the use of eprosartan to treat isolated systolic hypertension.

Method Of Treating Isolated Systolic Hypertension

View page
US Patent:
20070129415, Jun 7, 2007
Filed:
Feb 12, 2007
Appl. No.:
11/673605
Inventors:
David BROOKS - West Chester PA, US
Giora Feuerstein - Wynnewood PA, US
Eliot Ohlstein - Glenmoore PA, US
Robert Ruffolo - Spring City PA, US
International Classification:
A61K 31/4178
US Classification:
514397000
Abstract:
This invention relates to the use of eprosartan to treat isolated systolic hypertension.
Control profile
Eliot H Ohlstein from Glenmoore, PA, age ~70 Get Report